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Acute B lymphoblastic leukemia (B-ALL) is one of the most common types of child-
hood cancer worldwide and chemotherapy is the main treatment approach. Despite 
good response rates to chemotherapy regiments, many patients eventually relapse and 
minimal residual disease (MRD) is the leading risk factor for relapse. The evolution of leu-
kemic clones during disease development and treatment may have clinical significance. 
In this study, we performed immunoglobulin heavy chain (IGH) repertoire high throughput 
sequencing (HTS) on the diagnostic and post-treatment samples of 51 pediatric B-ALL 
patients. We identified leukemic IGH clones in 92.2% of the diagnostic samples and 
nearly half of the patients were polyclonal. About one-third of the leukemic clones have 
correct open reading frame in the complementarity determining region 3 (CDR3) of IGH, 
which demonstrates that the leukemic B cells were in the early developmental stage. We 
also demonstrated the higher sensitivity of HTS in MRD detection and investigated the 
clinical value of using peripheral blood in MRD detection and monitoring the clonal IGH 
evolution. In addition, we found leukemic clones were extensively undergoing continu-
ous clonal IGH evolution by variable gene replacement. Dynamic frequency change and 
newly emerged evolved IGH clones were identified upon the pressure of chemotherapy. 
In summary, we confirmed the high sensitivity and universal applicability of HTS in MRD 
detection. We also reported the ubiquitous evolved IGH clones in B-ALL samples and 
their response to chemotherapy during treatment.
Keywords: acute B lymphoblast leukemia, minimal residual disease, high throughput sequencing, IGH, clonal 
evolution
Abbreviations: ALL, acute lymphoblastic leukemia; B-ALL, B cell lineage ALL; BM, bone marrow; CDR3, complementarity 
determining region 3; FCM, flow cytometry; FR3, framework region 3; HTS, high throughput sequencing; IGH, immuno-
globulin heavy chain; MRD, minimal residual disease; ORF, open reading frame; PB, peripheral blood; RQ-PCR, real-time 
quantitative polymerase chain reaction; TCR, T cell receptor.
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inTrODUcTiOn
Acute lymphoblastic leukemia (ALL) is one of the most common 
malignant disease in children worldwide and represents approxi-
mately a quarter of cancer diagnoses among children younger 
than 15 years. During the past 25 years, there has been a gradual 
increase in ALL incidence according to the National Cancer 
Institute’s Surveillance, Epidemiology, and End Results (SEER) 
Program, as well as published reports (1). About 85% of pediatric 
ALL is classified as B cell lineage ALL (B-ALL). With the improve-
ment of treatment strategies, the 5-year survival rate of ALL has 
greatly increased from 57.2% during 1975–1977 to 91.8% during 
2004–2010 according to the cancer statistics by National Institutes 
of Health (NIH). In spite of increased cure rates in pediatric ALL, 
relapse still occurs in approximately 15–20% of patients (2), and 
minimal residual disease (MRD) is the main risk factor for ALL 
relapse. Therefore, MRD level has become an important clinical 
index for doctors to assess treatment response, to adjust the treat-
ment strategy during ALL therapy, and to predict relapse after 
treatment (3–8). On the other side, some patients are likely to be 
over-treated and experience serious side effects of chemotherapy. 
Thus, it is important to consider increasing cure rates together 
with decreasing toxicity during treatment, and monitoring MRD 
can provide great help.
Flow cytometry (FCM), fusion genes analysis, and molecular 
analysis of immunoglobulin (Ig) or T cell receptor (TCR) gene 
rearrangements are three principal methods for MRD detection 
in childhood ALL. FCM is a method based on the immunophe-
notype, which distinguishes the ALL cells from the normal leu-
kocytes by the cell markers they expressed (9). FCM has become 
a widely used method for clinical investigations due to the 
rapidity of method, but the immunophenotypic shifts induced by 
chemotherapy could affect the confidence and accuracy of MRD 
detection (10, 11). Detection of MRD based on the gene fusions 
caused by chromosomal translocation can achieve very high 
sensitivity, but this method only applicable to ALL patients with 
chromosomal translocations that are identified only in a minority 
of patients (12). Another ALL MRD detection method is based on 
the antigen receptor gene rearrangement by real-time quantita-
tive polymerase chain reaction (RQ-PCR) (13). This method is 
also very sensitive (14), but is laborious and time-consuming 
due to the need to design patients-specific primers (15). Besides, 
false-negative result due to clonal evolution is a major problem 
using unique Ig or TCR rearrangement as RQ-PCR target for 
MRD detection (7). Several studies have reported the application 
of high throughput sequencing (HTS) of TCR repertoire or Ig 
repertoire in MRD detection (16–18). Bone marrow (BM) is the 
most used specimen for MRD detection in leukemia; however, it 
has been proposed that peripheral blood (PB) might represent 
a more convenient specimen for monitoring MRD. For acute 
myeloid leukemia (AML), Maurillo et al. showed that PB could 
be used as the cell source for MRD detection using FCM, and 
MRD levels in PB were positively correlated with MRD measured 
in BM (19). Coustan-Smith et al. (20) demonstrated PB may be 
used to monitor MRD in T-lineage ALL patients. By contrast, in 
B-lineage ALL patients, PB did not work well for MRD detection, 
but still provided valuable prognostic information (20). However, 
these studies did not analyze and describe the feasibility and clini-
cal significance of MRD detection using PB by HTS.
Tumors, including hematological tumors, are composed of 
heterogeneous subpopulations, and tumors with higher hetero-
geneity had higher rates of resistance to chemotherapy compared 
with tumors with lower phenotypic variability (21). Some of the 
subpopulations were produced due to on-going cancer clonal 
evolution in disease development and disease treatment. The 
massive evolution of the leukemic cell plays a pivotal role in 
disease progression and relapse (22), and a prior study reported 
the mechanisms of clonal evolution in B-ALL (23). The evolution 
related to V gene replacement in pre-treatment B-ALL samples 
and the clinical significance has been reported by several studies 
(17, 24). However, to our knowledge, the extent and dynamics of 
the clonal evolution of leukemic cells during treatment, as well as 
its clinical significance, have never been reported.
In this study, we investigated the immunoglobulin heavy 
chain (IGH) repertoires of 51 B-ALL patients before and during 
the chemotherapy using HTS technology. We identified disease-
bearing IGH rearrangements in 92.2% of the patients and half of 
the patients harbored two or more leukemic IGH clones. Those 
clonal B cells were in the early developmental stages. We also ana-
lyzed the IGH repertoires of nine diagnostic samples in the RNA 
level and the result showed that all the disease-causing clones, 
including those without function, can transcribe mRNA. Next, 
we demonstrated the high sensitivity of HTS technology in MRD 
detection and the prognostic value of MRD detection using PB 
samples. Lastly, we analyzed the evolved IGH clones induced by 
V gene replacement, and at the same time evaluated the changes 
of the numbers and the frequencies of those evolved IGH clones 
during treatment.
MaTerials anD MeThODs
Patients and samples
We studied 51 childhood B-ALL patients diagnosed in Shenzhen 
Children’s Hospital. BM specimens and (or) PB were obtained 
at diagnosis and during treatment, and in total 169 specimen 
were collected (Table S1 in Supplementary Material). The study 
was carried out in accordance with the recommendations of 
Declaration of Helsinki and was approved by BGI-IRB. Written 
informed consent was obtained from the parent(s) or guardian(s) 
of each child. All the BM and PB specimens were collected in 
heparin and stored at −80°C until analysis was conducted. High-
quality gDNA were extracted from the frozen BM and PB samples 
using DNA Blood mini kit (QIAGEN, Cat. no.51106).
Disease risk stratification
B-ALL patients were stratified into three risk groups according to 
the following criteria:
Standard risk (SR): (1) age at diagnosis between 1 and 6 years; 
(2)WBC <  20 ×  109/L; (3) good prednisone respond (GPR) at 
7 days treatment, peripheral blasts < 1.0 × 109/L at day 8; (4) BM 
aspiration results M1 (blasts < 5%) or M2 (blasts 5% ~25%) at 
day 15 post induction; and (5) BM aspiration results M1 at day 
33 post induction.
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Intermediate risk (IR): (1) age at diagnosis <1 year or ≥6 years; 
(2) WBC ≥ 20 × 109/L; (3) GPR; (4) BM aspiration results M1 or 
M2 at day 15 post induction; (5) BM aspiration results M1 at day 
33 post induction; (6) reach to SR but BM aspiration results M3 
(blasts > 25%) on day 15 of induction therapy, and BM aspiration 
results M1 on day 33 of induction therapy.
High risk (HR): (1) IR but BM aspiration results M3 on day 
15 of induction therapy; (2) poor prednisone respond (PPR), 
peripheral blasts > 1.0 × 109/L at day 8; (3) BM aspiration results 
M2 or M3 at day 33 of induction; (4) t(9:22) (BCR/ABL) positive 
or t(4:11) (MLL/AF4); (5) testicle leukemia at diagnosis and did 
not clinically resolve by day 33 of chemotherapy; (6) large medi-
astinum mass at diagnosis, and did not completely resolve by day 
33; (7) central nervous system leukemia (CNSL) at diagnosis.
immunophenotyping and  
MrD Detection by FcM
Immunophenotyping and MRD detection by FCM was performed 
at KINGMED CENTER FOR CLINICAL LABORATORY. The 
red blood cells of BM samples were lysed to get nucleated cells. 
For MRD detection, BM nucleated cells were stained with the 
following monoclonal antibody combinations: (1) CD58 FITC, 
CD34 PE, 7AAD PerCP-CY5.5, CD10 PE-Cy7, CD19 APC, 
CD38 V450, CD45 V500; and (2) CD66c FITC, CD13+CD33 
PE, CD34 PerCP-CY5.5, CD10 PE-Cy7, CD19 APC, CD15 V450, 
CD45 V500. The labeled cells were analyzed using a BD CANTO 
II flow cytometer (Becton Dickinson, San Jose, CA, USA) with 
at least 100,000 events were acquired. Data were analyzed using 
BD FACSDiva (Becton Dickinson) and FCS Express (De Novo 
Software, Los Angeles, CA, USA) software. The compensation 
matrix was set up using BD CompBeads (Becton Dickinson) for 
fluorochrome-conjugated antibodies. Quality control was per-
formed using BD Cytometer Setup and Tracking Beads (Becton 
Dickinson).
high Throughput sequencing  
of IGH repertoire
The complementarity determining region 3 (CDR3) of the vari-
able regions of IGH was amplified by multiplex PCR. Concretely, 
the complete VDJ rearrangements of IGH were amplified from 
1200  ng gDNA with 12 degenerate forward primers annealed 
to the 55 functional variable genes (V) and 4 reverse primers 
annealed to the 6 functional joining genes (J) listed in the IMGT 
database. The primers have been carefully evaluated to minimize 
PCR bias, and were listed in Table S4 in Supplementary Material. 
PCRs (50 μL) were set up at 25 μL of 2× QIAGEN Multiplex PCR 
master mix, 5 μL of QIAGEN Q solution, 1 μL of 10 μM forward 
primer pool, 1 μL of 10 μM reverse primer pool, and 18 μL of 
67 ng/μL gDNA. The reaction cycling conditions were: 95°C for 
15 min, 30 cycles at 94°C for 30 s, 60°C for 90 s, and 72°C for 30 s, 
followed by a final extension at 72°C for 5 min. The target ampli-
fied products (120–200  bp) was purified by electrophoresis on 
2% agarose gel, and the Illumina Hiseq sequence adaptors were 
ligated. Then the sequencing libraries were sequenced with stand-
ard 2 × 150 paired end reads on Illumina Hiseq2500 platform.
analyses of the sequencing Data
Sequencing data were analyzed by the TCR and BCR repertoire 
analyzing pipeline IMonitor (25). About 2–5 million mapped 
reads (include correct V and J genes) remained after the above 
pipeline for each sample, and we used a random subset of 2 mil-
lion mapped reads for continued analysis. In order to remove the 
false IGH clones derived from sequencing error or contamination 
from other samples in the same Illumina sequencing lane, we fil-
tered the clonotypes with supported reads lower than the inferred 
average sequencing depth for every B cells in each sample. The 
average sequencing depth was inferred as following: first, the total 
input cell number for amplification was 2 × 105 cells, equating to 
1200 ng input gDNA. Second, we calculated the B cell number 
by multiplying the total input cell number by the B cell percent-
age (detected by FCM according the CD19 marker). Third, the 
average sequencing depth was inferred by dividing the total used 
reads (2 million) by the B cell number used in the sample. The 
CDR3s were classified as non-functional if frame-shift mutations 
or stop codons existing in CDR3 region.
MrD Detection by hTs
Similar to previous studies, we defined the CDR3s in diagnostic 
samples with frequency higher than 10% as leukemic clones 
(17, 18). In the post-treatment samples, we determined the MRD 
by calculating the frequencies of identical CDR3 sequences with 
the leukemic clones in the level of total nucleated cells. The MRD 
is calculated by multiplying the frequencies of leukemic clones by 
B cell percentage in the total nucleated cells, which is determined 
by FCM.
identifying the evolved IGH clones  
of leukemic clones
The method used by Gawad et al. (24) was used to identify the 
evolved IGH clones from the leukemic clones with minor modi-
fication. Concretely, the evolved IGH clones were defined as: (1) 
identical J sequence with the leukemic clone; (2) share at least 
eight bases of identical NDN sequence with the leukemic clone; 
(3) different V gene from the leukemic clone; (4) more than three 
mismatches in CDR3 sequence if the evolved IGH clone had the 
same length as the leukemic clone.
resUlTs
clinical characteristics  
of the B-all Patients
We randomly, without any prior knowledge of the clonal IGH 
rearrangement existence, collected 51 pediatric B-ALL patients 
in total. According to the disease risk stratification criteria, 19 
of them were classified as SR, 18 as IR, and 14 as HR (Table S1 
in Supplementary Material, details in the section “Materials 
and Methods”). The characteristics and clinical information of 
the patients, including diagnostic age, gender, and cytogenetics 
were collected and listed in Table S1 in Supplementary Material. 
Ninety-six percent of patients (49/51) were aged between 1 and 10, 
and 2 patients were more than 10 years old. Among the patients, 
35.3% (18/51) were females, and 23.5% (12/51) were diagnosed 
FigUre 1 | correlation of B-all disease risk with the number of leukemic clones in diagnostic sample. HR, high risk; IR, intermediate risk; SR, standard 
risk; “mono_clone,” just one leukemic clone in the diagnostic sample; “poly_clone,” two or more leukemic clones in the diagnostic sample.
TaBle 1 | leukemic clones identification in 52 B-all patients.
Disease IGH clone number of patients Percentage
0 4 7.8
1 23 45.1
>1 24 47.1
Total 51 100
4
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with TEL-AML1 gene fusion. All the 51 patients showed good 
treatment result after 2–3 months of chemotherapy.
clonal leukemic IGH identification  
in Pre-Treatment BM samples
According to the definition of leukemic clones (see Materials 
and Methods), we identified leukemic IGH CDR3s with com-
plete V–D–J rearrangement in a frequency of above 10% in the 
diagnostic BM samples in 47 of 51 patients (92.2%). Of the 47 
patients with leukemic IGH clones, 24 had two or more leukemic 
clones (Table 1; Table S2 in Supplementary Material). Therefore, 
we identified 77 leukemic clones from the 47 patients in total 
(Table S2 in Supplementary Material). The four patients without 
identification of leukemic clones did not show any significantly 
distinct immunophenotypes. They may harbor incomplete VDJ 
rearrangement, or use the pseudo genes to recombine VDJ which 
cannot be amplified by our multiplex PCR primer set. We then 
investigated if the number of leukemic clones related with the 
disease risk. The result showed that more patients in SR group 
have just one disease clone; however, more patients in HR group 
have two or more disease clones (Figure 1).
Because B-ALL is a kind of cancer originating from the 
immature stage of B cells, we investigated if the leukemic 
IGH rearrangements underwent positive selection. Of the 77 
leukemic clones, 28 (about one-third) were functional with 
correct open reading frame (ORF) in the CDR3, and the other 
49 were classified as non-functional due to the occurrence of 
frame-shift or stop-codon mutations in the CDR3 (Table S2 in 
Supplementary Material). The ratio of functional to non-func-
tional clones was proportional with that expected by chance. 
The data above demonstrated that these B cells were immature 
precursor B cells without experiencing positive selection. We 
next compared the mRNA transcription of the functional and 
non-functional leukemic clones by sequencing the IGH reper-
toire of RNA extracted from the same BM specimen of nine 
patients. All the leukemic clones, including the non-functional 
clones, were detected in RNA with high frequency. Surprisingly, 
the transcription of non-functional leukemic clones was not 
eliminated or even decreased compared with the functional 
clones (Figure S1 in Supplementary Material), implying the 
resistance to the nonsense mRNA decay pathway (26, 27). 
However, compared with the frequencies in DNA samples, the 
frequencies of most leukemic clones in RNA decreased largely, 
both for functional and non-functional ones (Table 2), which 
could be due to decreased transcription of the pre-B cells (28), 
including B-ALL leukemic cells, and it is consistent with other 
report (29).
TaBle 2 | The frequency of leukemic clones in Dna and rna of the same 
bone marrow samples.
Patients leukemic 
clone iD
leukemic clones 
frequency in Dna (%)
leukemic clones 
frequency in rna (%)
P001 P001B 35.79 10.94
P001A 15.42 4.30
P001D 14.82 3.07
P001C 14.80 4.59
P005 P005 84.56 34.53
P006 P006 78.62 30.36
P007 P007A 45.52 27.39
P007B 40.96 1.16
P008 P008 90.87 20.19
P013 P013 25.12 11.79
P011 P011A 62.80 32.14
P011B 18.44 0.82
P011C 11.60 17.85
P015 P015A 27.64 10.02
P015B 10.59 4.30
P009 P009 87.59 19.61
Underline in the clone frequency means those clones with correct ORF.
FigUre 2 | comparison of MrD results detected by high throughput sequencing (hTs) with flow cytometry (FcM) assays. The samples were classified 
into three subsets: (1) MRD was detected positive by both HTS and FCM (left); (2) MRD were detected positive by HTS, but negative by FCM (middle); and (3) MRD 
was detected negative by both methods (right).
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comparison of MrD results Detected by 
hTs with FcM in Follow-up BM samples
With the precise IGH CDR3 sequence information of the leuke-
mic clones, we determined the frequencies of the leukemic clones 
in the follow-up BM samples. MRD based on the total nucleated 
cells was calculated by multiplying the frequency of the leukemic 
clone by the percentage of the B cells in total nucleated cells, which 
was determined by FCM for those samples. MRD levels and leu-
kemic clone frequencies decreased as treatment progressed (Table 
S2 in Supplementary Material and Figure S2 in Supplementary 
Material). With the purpose of evaluating the reproducibility 
of MRD detection by HTS, we performed two replicated MRD 
detections from equal BM specimen for three samples of two 
patients (P049-15, P049-33, and P051-15) and the result showed 
good reproducibility (Table S3 in Supplementary Material).
In order to assess the accuracy of the MRD detection by IGH 
repertoire HTS, we compared the detection results of HTS with 
the results detected by FCM, which were performed as the golden 
standard for MRD detection. All 34 MRD positive samples by 
FCM were detected as positive by HTS with similar MRD levels. 
Twenty-eight samples were detected as MRD positive by HTS, 
but MRD negative by FCM. The other 19 samples were MRD 
negative by both HTS and FCM. No MRD positive samples by 
FCM were detected negative by HTS, which demonstrated the 
higher sensitivity of HTS (Figure 2).
identification of leukemic clones and 
MrD Detection in the PB samples
Because BM aspiration can be painful, using PB instead of BM 
was evaluated for MRD detection. For 15 patients, we collected 
FigUre 3 | comparison leukemic clone frequency between bone marrow (BM) and peripheral blood (PB) specimens for diagnostic (a) and follow-up 
(B) samples. Values in the up left in (B) represent the number of samples in each quadrant.
6
Wu et al. MRD Detection and Evolution Analysis
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 403
both diagnostic BM and PB samples (Table S1 in Supplementary 
Material). We investigated if the leukemic clones identified in 
BM also existed in PB with high frequencies. The results revealed 
that all leukemic clones could be detected in PB with frequency 
of above 5%, except one clone, which was 18.405% in BM, but 
was just 0.810% in PB (Figure 3A). The Pearson correlation coef-
ficient between the frequencies of leukemic clones in diagnostic 
PB and BM was 0.7860. Therefore, PB can be used instead of BM 
in disease diagnosis and in leukemic clone identification for most 
patients.
To test MRD detection in PB specimens and to compare it 
with BM, post-treatment BM and PB samples were collected 
simultaneously in 15 pairs from 11 patients (Table S1 in 
Supplementary Material). We determined the frequencies of 
leukemic clones using the same method. In total, 22 leukemic 
clones were identified in pre-treatment BM samples for the 11 
patients, and 18 clones were positive in post-treatment BM. 
When detecting the 18 clones in the corresponding PB samples, 
12 clones were detected and other 6 were PB negative. When 
evaluating their frequencies in BM, 11/12 PB positive clones had 
relatively higher frequency than the 6 PB negative clones. Three 
leukemic clones were MRD negative in both PB and BM; one 
was positive in PB with clonal frequency of less than 0.01%, but 
was negative in BM. We then assessed if the leukemic clone fre-
quency in PB correlated positively with that in BM, and a weak 
correlation was found with a Pearson correlation coefficient of 
0.322 (Figure 3B). Overall, although PB could be used to detect 
MRD to some extent, the sensitivity of MRD detection using PB 
was still lower than using BM and it resulted in false negative for 
some samples.
Monitoring the evolved IGH clones  
of the leukemic clones Before  
and during Therapy
On-going change at the IGH gene is one of the most important 
ways leading to the diversity of cancer cells in B-ALL. After finish-
ing IGH variable (V) gene, diversity (D) gene, and joining (J) gene 
rearrangement during B cell development (30), the V segments 
upstream of the used V gene are still reserved, which make the 
V gene replacement possible by rearranging an upstream V gene 
with the complete V–D–J rearrangement. Because the loss of 
5′ recombination signal sequences (RSS) in D segment of the 
rearranged V–D–J exon, cryptic RSS within the used V gene is 
involved in V gene replacement, which effectively increases the 
length of the V–D–J junction of the new rearrangement (31). 
The identified evolved IGH rearrangements of leukemic clones 
in this paper could be generated by three different mechanisms. 
The first and second mechanisms are based on V replacement 
in IGH gene. The first mechanism is that the leukemic clone is 
the ancestral clonotype and the evolved IGH clones derived from 
continuous V replacement. In this situation, the V segment of the 
evolved IGH clones will be located at the upstream of the leuke-
mic clone, and the CDR3 length of evolved IGH clones would be 
longer than that of leukemic clone (31). The second mechanism 
is that the leukemic clone is produced by V replacement from a 
more ancestral pre-leukemic clonotype. In this situation, the V 
segment of leukemic clone will located at the downstream of the 
ancestral clone, and the CDR3 length of the leukemic clone would 
be longer than the ancestral clone. The third mechanism is that 
the ancestral (pre-leukemic) clone finished an incomplete D–J 
rearrangement of IGH locus, and the leukemic clone and other 
FigUre 4 | The evolved clones in pre-treatment and post-treatment bone marrow (BM) samples. (a,B) The number of evolved clones in pre-treatment (a) 
and follow-up (B) BM samples. Different colors indicate different relative position (green for upstream, orange for downstream, and blue for uncertain) for the evolved 
clonotypes compared to the leukemic clones. (c,D) The correlation between the leukemic clonal frequencies and the evolved clones in pre-treatment (c) and 
post-treatment (D) samples. The size of the point indicates the unique number of evolved clones from each leukemic clone, and colors in (D) indicated the time of 
BM obtained after the beginning of chemotherapy.
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evolved IGH clones underwent independent IGH V rearrange-
ment. Therefore, the CDR3 length of the leukemic clone and the 
evolved IGH clones would be comparable.
To explore the roles of these mechanisms, we assessed and 
compared the V segments used and the CDR3 length between 
the leukemic clones and the evolved IGH clones. In total, 51.62% 
of evolved IGH clones were mainly replaced by upstream V genes 
compared to 19.67% by downstream V segments (Figures 4A,B). 
For the evolved IGH clones using upstream V segments, most of 
the CDR3s were longer than the corresponding leukemic clones; 
however, the CDR3 lengths of the evolved IGH clones using 
downstream V segments were comparable with the leukemic 
clones (Figure S3 in Supplementary Material). The above result 
demonstrated that the evolved IGH clones we identified were 
produced mainly by the first mechanism; in addition, the third 
mechanism also contributed to the evolved IGH clones. Because 
the pre-leukemic clones were also important in leukemic devel-
opment and could lead to relapse of disease, we included all those 
evolved IGH clones in subsequent analysis.
In the diagnostic BM samples, we identified evolved IGH 
clones in most of the patients, and only two patients did not have 
evolved IGH clones. We also found that four leukemic clones were 
produced due to V gene replacement of the other four leukemic 
clones in three patients (Table S2 in Supplementary Material). 
The number of identified evolved IGH clones varied from 0 to 
4558 for each leukemic clone (Figure  4A), with 14 (18.2%) of 
the leukemic clones did not experience IGH evolution. When 
investigating the ORF of the evolved IGH clones, only 11.5% of 
those clones were functional with correct ORF, which is much 
lower than the proportion of the leukemic clones. The total fre-
quency of these clones varied from 0 to 38.55% for each leukemic 
clone (Figure 4C). There was a positive correlation between the 
FigUre 5 | comparison of evolved clones in PB and BM. (a) The number of evolved clonotypes identified in PB and BM of the same samples. “#” in the X-axis 
indicates follow-up samples. (B) The total frequency of evolved clones in PB and BM of the same samples. Brown triangles indicate follow-up samples.
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total frequency and the number of evolved IGH clones for each 
leukemic clone (Pearson’s r =  0.6661; Spearman’s r =  0.9851). 
Whether the number and frequencies of the evolved IGH clones 
were determined by the total number of the leukemic cells is an 
interesting question. We found that both the number (Pearson’s 
r = −0.0490) and total frequencies (Pearson’s r = −0.0985) of 
evolved IGH clones was not associated with the frequency of the 
cancer clone (Figure 4C). The association of evolved IGH clones 
with clinical features is another important question; however, we 
did not identify their correlation with disease characteristics in 
our dataset (Figures S4A,B in Supplementary Material).
We next investigated the dynamic change of the evolutionary 
IGH clones following chemotherapy treatment in BM. Forty-six 
percentage of the MRD positive samples contained evolved IGH 
clones, and we did not detect evolved IGH clones in MRD nega-
tive samples (Figure 4D). We also investigated the ORF of these 
evolved IGH clones, and the results showed only 12.7% of those 
clones were functional with correct ORF, which was similar to 
the proportion of evolved IGH clones in diagnostic samples. The 
total frequency of these evolved IGH clones showed very weak 
correlation with the frequency of leukemic clones (Pearson’s 
r =  0.2203, Figure  4D). Tracking the fluctuation of frequency 
ratios of the evolved IGH clones to the leukemic clones revealed 
the imbalanced response of leukemic clones and evolved IGH 
clones to chemotherapy. The ratios of total frequencies of evolved 
IGH clones to the frequencies of leukemic clones decreased dur-
ing treatment for most of clones; however, for several clones, 
the day 15 samples showed higher ratio than the diagnostic 
samples (Figure S5 in Supplementary Material), which may imply 
positive selection of the evolved IGH clones upon the pressure of 
chemotherapy in the begin of treatment. Interestingly, we found 
a significant number of evolved IGH clones newly emerged in the 
post-treatment samples (Figure S6 in Supplementary Material), 
even though these clones eventually disappeared with the nega-
tive detection of MRD after chemotherapy.
We compared the number and total frequency of evolved IGH 
clones in PB and BM of the same patients. The result showed 
that the number and total frequency of evolved IGH clones in PB 
were correlated positively with that in BM (Pearson’s r = 0.9941 
for number; Pearson’s r = 0.7154 for total frequency). However, 
for most samples, the total frequency of evolved IGH clones in PB 
was lower than that in BM (Figure 5). This result revealed that PB 
has the potential to serve as a non-invasive specimen to monitor 
clonal IGH evolution during therapy, but it may underestimate 
the frequency of evolved IGH clones.
DiscUssiOn
Leukemia is a clonal disease, and pediatric B-ALL is derived 
from an early stage of B cell development. During early B cell 
development, the germline variable (V), diversity (D) and join-
ing (J) gene segments of Ig recombine and, therefore, each B 
cell obtains a particular combination of V–D–J segments (30). 
The random deletion at the end of germline segments and the 
random insertion of nucleosides between the V–D and D–J gene 
segments during rearrangement creates huge diversity of CDR3 
of the IGH gene. According to the above production mechanism 
of the antibody diversity, the CDR3 sequence of the IGH can 
be used as a unique proxy to distinguish different B cells. IGH 
sequence has been used as a tumor-specific biomarker to detect 
MRD for decades by conventional polymerase chain reaction 
(PCR) or RQ-PCR (7, 32, 33). Since the development of immune 
repertoire HTS technology in 2009 (34–36), several studies have 
tried to detect MRD of pediatric ALL, including T-ALL (36) 
and B-ALL (17, 18) using this technology. In order to evaluate 
the wider applicability of this technology, we detected the MRD 
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of B-ALL patients with different treatment days using immune 
repertoire HTS. We also investigated the evolved IGH clones in 
pre-treatment and post-treatment samples.
We identified clonal IGH rearrangements in 92.2% of the 
unselected cohort of childhood B-ALL patients (Table  1). The 
four patients without clonal IGH rearrangement detected did not 
show any difference in clinical phenotype and FCM result. It is 
possible that these leukemic cells were in an earlier developmen-
tal stage in those patients, just finished the D–J rearrangement, 
but not the complete V–D–J rearrangement, which has been 
observed in previous studies (17, 18, 37). It is also possible those 
leukemic cells were in the earliest recognizable B-lineage cells, 
which did not begin the rearrangement. Previous study had also 
reported that most of the childhood B-ALL (>83%), but not all 
the patients, had IGH gene rearrangement (7, 33). Therefore, even 
though the high sensitivity of MRD detection using HTS, the 
limitation in failure to diagnose the pro-B-ALL, which consists of 
about 10% of B-ALL patients, indicated that FCM was still needed 
to accurately diagnose B-ALL and detect MRD for those patients.
Importantly, we found that disease risk of B-ALL is related to 
the number of leukemic clones in diagnostic samples for the first 
time. Concretely, sample with more leukemic clones indicates 
higher disease risk, which means slower reaction to chemo-
therapy reagent (Figure  1). More leukemic clones may imply 
higher RAG1 and RAG2 activity, which could not only target the 
Ig gene but also the non-Ig gene (such as tumor suppressor gene 
IKZF1, CRLF2, BTG1, etc.), and lead to the genomic instability 
according to Swaminathan et  al. (23). They reported that high 
RAG1 mRNA expression predicted poor ALL patient outcome, 
which could explain our result.
During the V–D–J rearrangement of IGH in B cell develop-
ment, the random deletion and addition of nucleotides between 
V–D and D–J segments at the time of joining could result in vari-
ability at the junctions and different ORF in CDR3. The possibility 
that the length of the CDR3 is exact multiple of three nucleotides 
is one-third expected from random rearrangement. Therefore, in 
theory, only one in three IGH rearranged B cells could make an 
in-frame and functional rearrangement before selection, which 
has been demonstrated previously (38). In our study, about 
one-third of the disease clones had in-framed CDR3 ORF, and 
two-thirds of the disease clones had frame-shift mutation in the 
CDR3 (Table S2 in Supplementary Material). Therefore, our data 
are consistent with random recombination and suggested that 
leukemic cells were in the very early development stage without 
experiencing positive selection.
In the normal B cell development, precursor-BCR (pre-BCR) 
checkpoint controls critical B-cell developmental processes and 
is essential to make sure that the B cells develop into mature B 
cell (39–41). The pre-BCR has to be expressed on the cell surface 
to induce the B cell to pass this checkpoint. In order to pass 
the checkpoint, the B cell should complete in-frame IGH VDJ 
recombination to express a functional Pre-BCR. If a precursor 
B cell possesses an out-of-frame IGH rearrangement, there is no 
pre-BCR expressed on the surface of the B cell, therefore, the cell 
does not receive necessary survival signals, and it will undergo a 
programed cell death. In our study, we found that two-thirds of the 
leukemic cells do not have functional IGH V–D–J rearrangement 
(Table S2 in Supplementary Material), but they survived the 
selection and proliferated to clonal cells. A similar result was also 
observed in another study in BCR-ABL1 positive B-ALL cells 
(42), which reported only 3 out of 12 BCR-ABL1 positive B-ALL 
cases harbored potentially functional IGH gene rearrangements. 
Several studies have reviewed that leukemic B cells could manage 
to evade the pre-BCR checkpoint and avoid clonal extinction by 
mimicing or bypassing the Pre-BCR signaling pathway (43–45).
As to MRD detection, our data demonstrated the robustness 
of HTS similar to previous studies (16–18). Compared to FCM, 
HTS did not show false-negative results, and the HTS method 
can detect MRD at levels lower than 0.01%, which cannot be 
detected by FCM (Figure 2). In general, our study confirmed the 
wide applicability of HTS in MRD detection and higher sensitiv-
ity than FCM. There were eight post-treatment samples, whose 
MRD were higher than 0.1% by HTS, but were reported negative 
in the FCM detection. Wu et al. discovered a similar phenomenon 
in their study, and verified and explained that this is possible due 
to immunophenotypic normalization induced by therapy (17). 
Because most the patients in our cohort were followed up for less 
than 2 years, and no patient relapsed, we cannot assess the clinical 
significance of the higher MRD detection sensitivity using HTS 
in this panel. Wu et al. discussed the prognostic significance by 
reviewing previous studies, and concluded that very low-level 
MRD detected by HTS is likely to be meaningful and, therefore, 
they suggests that these patients should be closely monitored (17).
To date, BM is the most used specimen for MRD detection in 
leukemia; however, it has been proposed that PB might represent 
a more convenient specimen for monitoring MRD. In this study, 
we found that for samples with relatively high leukemic clone 
frequency in BM (approximately above 1%), PB samples could 
detect MRD but with relatively lower MRD levels than BM samples 
(Figure 3), and this result agreed with the Coustan-Smith et al.’s 
study in B-ALL (20). Overall, there is a false-negative rate and 
the MRD level could be underestimated in PB, which limited 
the application of PB in clinic for MRD detection today. Larger 
cohort with more comprehensive design is needed to determine 
how PB sample should be used directly in clinic. For example, 
the MRD level in PB 7 day post-treatment may correlate well 
with the MRD level in BM 15 day post-treatment; therefore, it is 
possible we could use the MRD level in PB 7 day post-treatment 
to predict the prognosis of leukemia. Notably, in our study, one 
negative leukemic clone in BM was found to be positive in PB, 
which implied PB might provide compensated prognostic value 
to BM.
Clonal evolution is an important question in leukemia devel-
opment and treatment. In this study, we identified evolved IGH 
clones induced by V replacement, and also the correlation of 
those clones with the frequencies of leukemic clones in diagnostic 
BM samples (Figure 4C). More importantly, we found that four 
leukemic clones were produced due to V gene replacement from 
other leukemic clones (Table S2 in Supplementary Material), 
which suggested that evolved IGH clones could expand greatly 
and lead to disease relapse if not eliminated during treatment. 
We also investigated the reaction of those evolved IGH clones 
during chemotherapy. Most of the day 15 and part of the day 
33 post-treatment samples contained evolved IGH clones 
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(Figure 4D) and abundant new evolved IGH clones not present 
in the diagnostic samples emerged upon the pressure of therapy 
(Figure S6 in Supplementary Material), which demonstrated that 
chemotherapy can induce continuous evolution of the leukemic 
cells and increase the heterogeneity of cancer. When investigating 
the response of evolved IGH clones to chemotherapy, both the 
clones identified in pre-treatment samples and those newly gener-
ated during treatment decreased during the course of therapy and 
disappeared when the MRD was negative (Figure 4D). Therefore, 
those evolved IGH clones were also therapy sensitive in primary 
cancer, which indicate good prognosis of those patients. However, 
we cannot make sure if a clone harboring an evolved IGH gene 
actually is to be equaled to the generation of a new clone with new 
genomic variants. In order to validate this correlation, single-cell 
sequencing used by Gawad et al. (46) is required to investigate 
the genome-wide somatic variants and the IGH DNA sequence 
of each single cell.
In this paper, we confirmed the wide applicability and 
higher sensitivity of HTS in MRD detection of B-ALL patients. 
Considering the invasiveness of BM extraction, we assessed the 
value of using PB as MRD detection specimen, and suggested 
that although MRD in PB could not represent the exact MRD 
level of the patients, PB could be used to evaluate the response of 
cancer cells to chemotherapy in the beginning of the treatment. 
During the disease development and disease treatment, cancer 
cells could evolve and generate high genetic heterogeneity of 
genome, including IGH gene. We identified many evolved IGH 
clones in the diagnostic samples. However, nearly all those 
evolved IGH clones decreased with on-going treatment and 
disappeared when the MRD became negative in these samples. 
It is possible some of those evolved IGH clones could lead to 
relapse of the disease.
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